Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …

The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …

Background The prognosis for patients with relapsed or refractory diffuse large B-cell
lymphoma (DLBCL) is poor. Glofitamab is a bispecific antibody that recruits T cells to tumor …

Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …

Background Patients with large B-cell lymphoma (LBCL) primary refractory to or relapsed
within 12 months of first-line therapy are at high risk for poor outcomes with current standard …

Natural killer (NK) cells comprise a unique population of innate lymphoid cells endowed with
intrinsic abilities to identify and eliminate virally infected cells and tumour cells. Possessing …

In the last decade, Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as a
promising immunotherapeutic approach to fight cancers. This approach consists of …

Background B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T-
cell therapies have generated responses in patients with advanced myeloma, but relapses …

Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated
impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma …

PURPOSE Epcoritamab is a subcutaneously administered CD3xCD20 T-cell–engaging,
bispecific antibody that activates T cells, directing them to kill malignant CD20+ B cells …